Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions

Inclusion Criteria: * Age ≥18 years and ≤ 75 years, male or female without pregnancy; * Patients with clinical evidence of asymptomatic heart disease, stable or unstable angina, or old myocardial infarction; * De novo lesions of native coronary arteries; * Target vessel diameter between 2.25mm and 4.5 mm, and target lesion length ≤ 60mm by visual estimation; * Target lesion diameter stenosis ≥ 70% by visual estimation; * Each target lesion must be implanted the same stent (CRE8); * Patients is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG); * Patients with left ventricular ejection fraction ≥40%; * Patients who can understand the nature of the study, agree to participate and accept angiographic and clinical follow-up, and have provided written informed consents. Exclusion Criteria: * Patients with acute myocardial infarction (AMI) within 72 hours; * Chronic total occlusion lesion (TIMI flow 0 before procedure), Left main disease and/or triple-vessel lesion that might require treatment; * Heavily calcified or tortuous lesions which cannot be successfully pre-dilated, and lesions which are not suitable for stent delivery and deployment; * In-stent restenosis; * Thrombotic lesions; * Patients who had received any other stent in the past one year; * Patients with acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl); * Patients with cardiogenic shock, acute infection, known bleeding or coagulation disorder, or with a history of active gastrointestinal bleeding, ulcer, cerebral hemorrhage or subarachnoid hemorrhage and stroke within 6 months; * Patients who allergic to aspirin, clopidogrel, ticagrelor, ticlopidine, heparin, contrast agent, sirolimus, polymer, Co-Cr alloy, or with contraindication to aspirin or clopidogrel or ticagrelor; * Patients with life expectancy less than 1year; * Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint; * Patient is in the opinion of the investigator, unable to comply with the requirements of the study protocol; * Patients who had underwent heart transplant surgery.